Avatar photo

Dr. G. Bozet, MD

Prevalence of steatosis and fibrosis in young adults in the UK

The study by KWM Abeysekera et al. (Population Health Sciences, Bristol Medical School, University of Bristol, and University Hospitals Bristol NHS Foundation Trust, Bristol, UK) is the first to determine the prevalence of NAFLD in young adults with use of transient electrography, in an age group in which NAFLD burden is poorly characterized...
Read MorePrevalence of steatosis and fibrosis in young adults in the UK

Hepatic fibrosis, cardiometabolic risk factors: The Framingham Heart Study

Liver stiffness, as assessed by vibration-controlled transient elastography (VCTE), correlates with hepatic fibrosis, an important predictor of liver-related and all-cause mortality. Although liver fat is associated with cardiovascular risk factors, the association between hepatic fibrosis and cardiovascular risk factors is less clear...
Read MoreHepatic fibrosis, cardiometabolic risk factors: The Framingham Heart Study

HSI screening for metabolic steatopathy in patients with T2D

The purpose of this study by H. Fennoun et al. (University Hospital, Casablanca, Morocco) was to determine the interest of hepatic steatosis index in the detection of hepatic steatosis in patients with type 2 diabetes in order to establish an appropriate screening program of this disease in the population of diabetics hospitalized in Morocco...
Read MoreHSI screening for metabolic steatopathy in patients with T2D

Machine learning-based approach to liver histology assessment

Manual histologic assessment is currently the accepted standard for diagnosing and monitoring disease progression in nonalcoholic steatohepatitis (NASH), but is limited by variability in interpretation and insensitivity to change. A. Taylor-Weiner et al. (PathAI, Boston, Massachusetts, USA) describe here a machine learning-based approach to liver...
Read MoreMachine learning-based approach to liver histology assessment

Mechanisms, screening, prevention, and management of CVD in patients with NAFLD

Cardiovascular disease, rather than liver decompensation, remains the leading cause of morbidity and mortality in patients with NAFLD and NASH. A significant proportion of the cardiovascular risk in NASH is likely attributable to shared metabolic risk factors. Nevertheless, there is much interest in understanding the independent contribution...
Read MoreMechanisms, screening, prevention, and management of CVD in patients with NAFLD